C-MHT7Longevity Biotech
immune rebalancing, Hybridtides, precision neuroscience
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-MHT7
C-MHT7C-MHT7immune rebalancing, Hybridtides, precision neuroscience
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Phase I a/b SAD/MAD study to evaluate safety and tolerability of LBT-3627 in both healthy volunteers and Parkinson's patients.
This study compares a comprehensive panel of immunological biomarkers between Parkinson's disease patients and healthy, environmentally matched participants. This unique study design provides the ability to control for differences in environment between study subjects. The goal of this study is to 1) identify a specific set of immunological markers that correlate with a clinical diagnosis of Parkinson's disease and 2) stratify patients by disease severity using these same biomarkers.
Longevity Biotech Awarded $225K Phase I SBIR Contract From NHLBI/NIH to Develop 5A apoA-I Mimetic Peptide for Treatment of Severe Asthma - Longevity Biotech Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM Newsroom Longevity Biotech Awarded $225K Phase I SBIR Contract From NHLBI/NIH to Develop 5A apoA- … peptide that will become the subject of a future Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) initially focused on patients who do not respond to standard corticosteroid treatment. “We are honored to be selected by the NHLBI/NIH to help develop this program, which expands both our immunological portfolio as well as our capabilities in less-invasive peptide delivery,” said Dr. Scott Shandler, Ph.D., co-founder and CEO of Longevity B
Neurodegenerative Disease | Longevity Biotech | Approach Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM Menu Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications Precision Neuroscience Longevity Biotech’s Precision Neuroscience Platform allows for the interrogation of the ‘fitn
Longevity Biotech, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Longevity Biotech, Inc. Holding Company | 2010 | Pennsylvania, United States | < 10 | www.longevitybiotech.com Holding Company | 2010 | Pennsylvania, United States | < 10 | www.longevitybiotech.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Other Diseases Nervous System Diseases Immune System Diseases Synthetic peptide Disease domain score … nd VIPR2). Although the use of native VIP facilitates neuroprotection, clinical application of the hormone is limited due to VIP's rapid metabolism and inability to distinguish between VIPR1 and VIPR2 receptors. In addition, activation of both receptors by therapeutics may increase adverse secondary toxicities. Therefore, we developed metabolically stable and receptor-selective agonists for VIPR1 and VIPR2 to improve pharmacokinetic and pharmacodynamic therapeutic end points. … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Longevity Biotech | Neuroscience Research | Contact Us Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM Contact Us 730 S 43rd St Philadelphia, PA 19104 Phone: 215-689-1042 Email Us Notice: JavaScript is required for this content. COLLABORATORS Privacy Policy | Cookies Policy | Terms & Conditions li
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Hybridtide Collaborators | Longevity Biotech Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM Longevity Biotech is proud to partner with the following organizations leveraging our product portfolio and our Hybridtide™️ and Precision Neuroscience Biomarker platforms to improve their product profiles. If
Longevity BioTech Market Report 2026 - Research and Markets Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscriptions Expe … , Advanced Drug Screening 9.4. Global Longevity BioTech Market, Segmentation by Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion Healthcare, Biotech, Pharmaceuticals, Wellness, Aging Population 9.5. Global Longevity BioTech Market, Segmentation by End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion Clinics, Hospitals, Research Institutes, Direct-to-Consumer 9.6. Global Longevity BioTech Market, Sub-Segmentation of Longevity Cons … erative Medicine; Multi-Omics Analysis Platforms; Advanced Drug Screening 4) By Application: Healthcare; Biotech; Pharmaceuticals; Wellness; Aging Population 5) By End User: Clinics; Hospitals; Research Institutes; Direct-To-Consumer Subsegments: 1) By Longevity Consultation: Initial Health Assessment; Personalized Longevity Planning; Lifestyle And Nutrition Counseling; Risk Assessment And Mitigation Planning; Follow-Up Longevity Monitoring; Genetic And Epigenetic Review 2) B … nology Related Reports Biotechnology Market Report by Product Type, Technology, Application, and Region 2026-2034  Report 138 Pages April 2026 Global From €3641 EUR $3,999 USD £3,137 GBP Biotechnology Market in the US 2025-2029  Report 170 Pages January 2025 United States From €2276 EUR $2,500 USD £1,961 GBP North America Biotechnology Market Report by Product Type, Technology, Application, Countries and Company Analysis 2025-2033  Report 200 Pages Sep … ongevity BioTech Market Report 2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-patt
Longevity Biotech Presents at Breakout Labs Portfolio Day - Longevity Biotech Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM Newsroom Longevity Biotech Presents at Breakout Labs Portfolio Day By kapp No Comments March 8th, 2016 – Cambridge, MA Longevity Biotech Presents at Breakout Labs Portfolio Day
Main | Insilico Medicine Product of interest PandaOmics PandaOmics Box Chemistry42 Generative Biologics Science42:DORA inClinico I agree to Privacy Policy Required Field Please enter a valid email address Please enter a valid name Please enter a valid phone number Value is too small Send Request Required Field Please enter a valid email address Please enter a valid name Please enter a valid phone number Value is too small Main About Mission Leadership Board of Directors Scientific Advisory Board Security & IT Contact us Pharma.ai Pharma.ai Suite PandaOmics Generative Biologics Chemistry42 … essor, a member of Insilico Medicine's Scientific Advisory Board, won the Nobel Prize in Chemistry in 2013 for his groundbreaking work in protein structure and protein folding using computer modeling. In this lecture, Dr. Levitt describes how the work he began over 50 years ago has been vastly improved and expanded through the massive increase in computer speed and incredible advances in machine learning. He touches on OPUS-X and AlphaFold and how each contribution has advanc
Biopharmaceutical Company | Longevity Biotech | About Us Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM Menu About Us Leadership Team Board Of Directors Scientific Advisors Careers About Longevity Biotech Longevity Biotech, Inc. is focused on changing the established neuroscience paradigm. Instead of
Longevity Biotech: Separating Science from the Hype Biotech Industry News Categories Change Subscription Clinical Trials Contributor Policy Cookie Policy Cookie Policy Create Guest Post Create Link Insertion Create Post Admin Create Post Enterprise Elite Create Post Explorer Create Post Pulse Create Post Team Builder Create Press Release Post FAQs Health Tech Join and Publish Log In Membership Account Membership Billing Membership Cancel Membership Orders Your Profile Membership Checkout Membership Confirmation Membership Levels Membership Pricing News Pharma Post Submitted Privacy Policy Regu … 2025, Life Biosciences announced FDA clearance for its Investigational New Drug application for ER-100, a gene therapy delivering three Yamanaka factors via intravitreal injection for optic neuropathies, with first-in-human trials planned for early 2026. NewLimit, backed by Coinbase co-founder Brian Armstrong with $280 million in cumulative funding, reported by December 2025 that it was close to having clinic-ready reprogramming therapies for liver and immune system rejuvenat
Longevity Investor Network 2024 End of Year Update Back to lifespan Home Login Return to Lifespan Homepage Donate Login News Outlet Research Biology of Aging Artificial Intelligence Decentralized Science Biomarkers Lifestyle Interventions Supplements Mindfulness Exercise Sleep Diet Financial Blockchain Investing Advocacy Policy Public Outreach LRI News Interviews Op-Ed Editorial Editor’s Pick Rejuvenation Roundup Press Releases News Outlet Research Biology of Aging Artificial Intelligence Decentralized Science Biomarkers Lifestyle Interventions Supplements Mindfulness Exercise Sleep Diet … s for under $10M. The company’s bigger vision is to help pets, learn, and apply the technology to people. Its ‘Bits to Therapies’ pipeline identifies novel CAR-T assets faster than biology and uses dogs as a spontaneous disease model to increase the CAR-T cell therapy hit rate. Vivan Therapeutics : Vivan Therapeutics is a biotechnology company focused on developing innovative therapies for age-related diseases and conditions. It aims to leverage advancements in science
A4LI H-SPAN Summit D.C. - Alliance for Longevity Initiatives Skip to content Dr. Mehmet Oz’s Opening Remarks at A4LI’s 2025 Congressional Briefing Join A4LI Become a Member Become a Sponsor Get Involved Our Advocacy Publications Longevity Science Caucus Podcasts H-SPAN Podcast Scientific Spotlights About Events A4LI H-SPAN Summit D.C. Past Events A4LI Longevity Investors Summit A4LI 2025 D.C. Summit Recap DC Fly-In 2024 Geroscience Education Reception LogIn Join A4LI Become a Member Become a Sponsor Get Involved Our Advocacy Publications Longevity Science Caucus Podcasts H-SPAN Podcast Scienti … Sarah Ocañas 9:55 AM - 10:10 AM Sponsor Presentation Petr Šrámek LongevityTech Fund 10:10 AM - 10:45 AM Panel - Capital, Risk & Commercialization at the Longevity Investment Frontier Moderator Sara Dauber Sofie Wei, John Ramunas, Petr Šrámek 10:55 AM - 11:10 AM Sponsor Presentation Irina Conboy Generation Lab 11:10 AM - 11:45 AM Panel - Precision Longevity Medicine for Health & Performance Moderator Alina Rui Su Roschon Johnson, Jeffrey Gladden, Matt Kaeberlein 11:50 … and CEO FibroBiologics Petr Šrámek, MBA Co-Founder and Chairman, LongevityTech.fund Sarah Ocañas, PhD Assistant Professor, Department of Physiology University of Oklahoma Health Sciences Center Sharon Rosenzweig-Lipson, PhD CSO, Life Biosciences Sonia Arrison Chair of Board, A4LI Stephen B. Kritchevsky, PhD Toby R. Alligood, MD Endowed Professor in Geroscience Associate Dean for Research Development Wake Forest University School of Medicine Todd White Managing Director, The … tickets or the program, please reach out to us at [email protected] . Ticket Price Deadline Purchase Days 1 and 2 $750 Purchase by June 15, 2026 Single Day $400 Purchase by June 15, 2026 Recommended Hotel Arlo Washington DC 333 G St NW, Washington, DC 20001 Booking Link Become a Sponsor Partner with A4LI to drive important dialogues with Members of Congress around groundbreaking advancements in aging research and longevity science policies. As a sponsor, you’ll gain visibi … he small business community, Kesselring received the 2022 SBA District Director Award for his work supporting small business owners across the country through SCORE and affiliated organizations, with a particular focus on helping businesses establish an online presence during the COVID-19 shutdown. He is also an alumnus of the Goldman Sachs 10,00
$18 billion has been invested in longevity biotech over the past three years. 2026 is projected to add another $9 billion, while estimates of full longevity market value by 2030 range from $300… | Next Generation Medicine - Future of Longevity LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. Yo
The New Billionaire Bet Isn't AI — It's Longevity Biotech Sign Up For Newsletters Games Share a News Tip Featured Featured Breaking News White House Watch Daily Cover Stories 2026 Forbes World's Most Influential CMOs List Making It Their Way: Six TikTok Creators On Finding A High-Quality Content Strategy That Pays Off | Paid Program The Hidden Tax On Enterprise AI: 1 In 5 Workers Lose A Full Day Every Week | Paid Program Scaling AI Editorial Video Series Silicon & Steel Editorial Video Series Turning Pressure Into Progress For Your Small Business | Paid Program Uniting To Ad
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
BOLD, L'Oréal’s venture capital fund, invests in Timeline, a Swiss longevity biotech company | L'Oréal Finance Skip to main content COURS 388,00 € +0,01 % CAC 40 8384,87 -0,55 % Search en fr en fr Share price Financial calendar Individual Shareholders Become a shareholder Loyalty Bonus and Registered Shares Annual General Meeting Shareholder events The Letters to shareholders Consultation committee Frequently asked questions Investors & Analysts Results hub Strategic presentations Regulated informations ESG In the heart of L’Oréal News L’Oréal at a glance Governance Annual Report … isconnect News & event 16 January 2024 BOLD, L'Oréal’s venture capital fund, invests in Timeline, a Swiss longevity biotech company BOLD, L'Oréal’s venture capital fund, invests in timeline, a Swiss longevity biotech company 16 January 2024 - pdf 128.74 KB L’Oréal and Timeline today announced that L’Oréal’s strategic venture capital fund, BOLD, has acquired a minority stake in Timeline, a Swiss longevity biotech company. Timeline was founded in 2007 by Chris Rin … Opportunities for L’Oréal Development, is the global corporate venture capital fund of L’Oréal. Since its creation in 2018, BOLD has explored the frontier of beauty via strategic minority investments in promising startups across the beauty value chain. Its investment portfolio includes emerging brands as well as innovative companies in the domains of technology and biotechnology. For more information about BOLD, please visit: www.lorealboldventures.com About Timeline Timelin
%PDF-1.4 %���� 1 0 obj /Creator (Chromium) /Producer (Skia/PDF m141) /CreationDate (D:20260414015455+00'00') /ModDate (D:20260414015455+00'00')>> endobj 3 0 obj > endobj 4 0 obj > stream x�uO�n� |�+�Av >' ���Y�T�P�}�ihU� $�;��r�f8o ƿ�o8�!FX~����4B�/3h$���X�:x�C ���)���Z� ���! � �iEP!,�I&����YY_�����ع�Dᠰ�W�i{�}��� �F��L�7�BhV{Vol����*7�eT%���w� N �f��fQx~��gqj��zI �t[���t�Hu����{� endstream endobj 5 0 obj >>> endobj 6 0 obj > >]>> /Extend [true true] /Coords [794 336.90002 0 794 336.90002 397] /ShadingType 3 /ColorSpace /DeviceRGB>>>> endobj 7 0 obj >>> /BBox [0 0 595 842] /Grou
Raven.config('https://[email protected]/147999').install(); Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration | INN Connect with us Information About Us Contact Us Careers Partnerships Advertise With Us Authors Browse Topics Events Disclaimer Privacy Policy Australia North America World Login Investing News Network Your trusted source for investing success North America Australia World My INN Videos Companies Press Releases Private Placements SUBSCRIBE Reports & Guides Market Outlook Reports Investing Guides Button Resource Pre … where Dr. Eva Maria Lilli Brandtner is evaluating advanced cells for potential application in a diabetes therapy. The Austria -based event, which ran January 25-27, 2026 , brought together global scientists and clinicians focused on biological therapies for diabetes. EPITA stands as one of the world's flagship associations for networking on islet transplantation and beta cell replacement, making Avant's participation particularly significant for the emerging biotechn
Longevity Biotech | Life Sciences PA Close Who We Are About Us Meet Our Team Board of Directors Membership Membership Benefits Become a Member Member Directory Member News Advocacy The Voice for PA’s Life Sciences Policy Priorities Our Partners Action Center Life Sciences Events Events Calendar Overview of Events Submit Your Event to LSPA Sponsorship & Volunteer Opportunities Life Sciences Future 2026 Photo Gallery Podcast Resources Economic Impact Annual Report Purchasing & Savings Life Sciences Center Quarterly Newsletters Member Login Industry News Contact Us Who We Are About Us M … Partners Action Center Life Sciences Events Events Calendar Overview of Events Submit Your Event to LSPA Sponsorship & Volunteer Opportunities Life Sciences Future 2026 Photo Gallery Podcast Resources Economic Impact Annual Report Purchasing & Savings Life Sciences Center Quarterly Newsletters Longevity Biotech Back to Search Longevity Biotech Categories Biotech Pharmaceutical http://www.longevitybiotech.com About Longevity Biotech, Inc. (LBT) is a biopharmaceutica … they need to succeed. $ Life Sciences Events Events Calendar Overview of Events Submit Your Event Sponsorship & Volunteer Opportunities Life Sciences Future Photo Gallery The Voice for PA's Life Sciences Through public policy advocacy in Harrisburg and Washington, D.C., Life Sciences PA serves as the voice for more than 960 member organizations across Pennsylvania that are critical to improving patient care, improving health globally, and to the economic growth of the Com
Longevity Biotech Growth Driven by Cross-Sector Collaboration | Revive ME posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you a
%PDF-1.4 % ���� 4 0 obj > /PageLabels > ] >> /Outlines 2 0 R /Pages 1 0 R >> endobj 5 0 obj > endobj 6 0 obj > >> endobj 7 0 obj > stream x��TKkA �S����!����_sT|`���@!�`�.a6q�������#ɂ��43]]]�o��-Yä�m'ϘlhK��1����F:m��3�v\��ũ�ҽ�~�tLWH��Ż����i� 8��eM*���(N� �m �˵ ��E�o`������� �RL�'Ssq��^��#�����ٜ����K��� �1.�d��Ϲ�D&�O�ZTo�Y��2s����Kl >,�D@�M�����N�Cb9\6���>�֥ P2[Qr�j'*�-`Mҳ8�N�4�>�-u`�&�h$�j� v8 h�)K�Y�7 endstream endobj 9 0 obj 542 endobj 10 0 obj [ > >> ] endobj 17 0 obj > >> endobj 18 0 obj > stream x��WMo#56 '_7�q�Ь����r5[u%�J���lF�v� ~B�������
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Sponsorships Home, Menu UTC-7 English Apply now Home About Roadmap Donate Store Apply Contact Recommended Reading Local chapters Zero to One Course Bottlenecks Report How to Live Longer Podcast Terms of Service 501(c)3 Compliance Death sucks. Let's fight it. (A RELENTLESS TEAM) Support Our Mission To Accelerate the Longevity Revolution (TIERS) Sponsorship Levels 🫡 SUPPORTER $5,000 Sponsor 3 cohorts (1 yr) Logo on LBF website, retreat banners, pdfs Exclusive Swag 1X LBF Retreat Pass Sponsor Now 🤝 HERO $15,000 All Supporter benefits plus: Verbal thanks at retreats, podcasts, online sessio … nation receipts contact us: [email protected] The Longevity Biotech Fellowship is an IRS approved 501(c)3 nonprofit. Participation requires agreement to our Terms of Service .
Neurodegenerative Disease | Longevity Biotech | Approach Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM Menu Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications Publications Corporate A SYNTHETIC AGONIST TO VASOACTIVE INTESTINAL PEPTIDE RECEPTOR-2 INDUCES REGULATORY T CELL NEU
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Neuroprotective Agent | LBT-3627 | Longevity Biotech Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM Menu LBT-3627 Pipeline Pipeline Privacy Policy | Cookies Policy | Terms & Conditions linkedin © 2026 Longevity Biotech. All Rights Reserved Close Menu ABOUT LONGEVITY BIOTECH About Us Leadersh
Terms & Conditions - Longevity Biotech Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM Terms & Conditions Welcome to Longevity Biotech These terms and conditions outline the rules and regulations for the use of Longevity Biotech’s Website, located at longevitybiotech.com. By accessing th
Neurodegenerative Diseases Research | Longevity Biotech Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM PRECISION APPROACH TO ADDRESS NEURODEGENERATIVE DISEASES Learn More Parkinson's Disease Clinical Trial Learn More Pipeline Learn More Precision Neuroscience Learn More Hybridtide™ Platform Le
Biopharmaceutical Company | Longevity Biotech | About Us Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM Menu About Us Leadership Team Board Of Directors Scientific Advisors Careers Board Of Directors Co-Founder Sam Gellman Sam Gellman, Ph.D., is the co-founder of Longevity Biotech. He is the Ralph F. … University, his Ph.D. from Columbia University, and completed his postdoctoral fellowship at the California Institute of Technology. His academic research program has been recognized by many awards. Sam is a member of the US National Academy of Sciences, a fellow of the National Academy of Inventors and a fellow of the American Academy of Arts & Sciences. Director Ashish Khanna Ashish Khanna is president & CEO of Allosite Therapeutics. He has over two decades of expe … rectors and Scientific Advisory Boards as well as an Advisor to the NeuroImpact Fund for IASO Ventures. He previously served as Chief Medical Officer of Cerevel Therapeutics Holdings, Inc. (previously Nasdaq: CERE), a biopharmaceutical company, from January 2019 to August 2024 when it was acquired by AbbVie Inc. From November 2007 to January 2019, Dr. Sanchez held various roles of increasing responsibility at Otsuka Pharmaceutical Development & Commercialization, Inc., a … ounding Longevity, Scott was a venture capitalist at BioAdvance, an early stage fund, where he was responsible for therapeutics, diagnostic and biomarker opportunities. At PolyMedix, Scott assisted with their successful Series A fundraising activities. His work history includes Accenture’s (ACN) Pharmaceutical and Medical Products group, Merck Research Labs (MRK), and Inventa. Scott received his Ph.D. in Biochemistry and Molecular Biophysics from the University of Pennsylvani
Longevity Biotech Granted US Patent Covering Hybridtide Platform Technology for Stabilized Peptide Therapeutics | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Longevity Biotech Raises $3.7B in Q1 2026 | Raya Khanin PhD posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Linked … streamlining, shorter EMA timelines, FDA CMC flexibility for CGT. Sponsors who submit stronger dossiers earlier will have a structural advantage. 2. Animal testing paradigms shifting: FDA oncology NAMs guidance has direct relevance for how nonclinical packages and TRAs are built across pharma, cosmetics, and FMCG. 3. Guidance quietly becoming enforcement: the FDA Form 483 situation is a pattern we see repeatedly across jurisdictions when regulators raise the bar without form
Longevity progress in 2022 - quadraScope Ventures --> --> --> --> --> --> --> --> --> --> --> Skip links Skip to primary navigation Skip to content li > a"}'> Home Science Portfolio Team Videos LOGIN Toggle navigation Home Science Portfolio Team Videos Download PDF Longevity biotech progress in 2022 Despite the economic challenges of 2022, the emerging longevity biotech industry made impressive progress on several fronts, including positive results in clinical trials of senolytics and mitochondrial replacement therapies. Contents Unity succeeds at preventing blindness through senolytic therapy … returns for private investors, leaving it up to the philanthropic community to fund these important projects. Non-profits, including Dr. Aubrey de Grey’s new Longevity Escape Velocity Foundation ( LEVF ) will be undertaking some of this work. On a related topic, the NIH runs the Interventions Testing Program ( ITP ) to identify and validate treatments that extend lifespan and healthspan in mice. Unlike for-profit companies, programs like the ITP are known to be transparent a … is sponsored by the Saudi government. The foundation committed $1B per year to fund longevity research and invest in longevity biotech companies. In 2022, Hevolution awarded $8.5M to fund American Federation for Aging Research New Investigator Awards, $2M to sponsor Longevity Impetus Grants, $2.6M to support geroscience research in Saudi Arabia, and $5M to support grants reviewed by the National Institute on Aging. Publicly announced funding that we can account for amounts t
Healthspan Capital Home Home About About BLOG BLOG Contact Contact California, USA Rejuvenation is the future of medicine. Investing in early-stage longevity biotech ("LongBio") and regenerative medicine startups to extend healthy human lifespan . Invest IN OUR FUND Aging a new therapeutic target to treat disease. A new wave of biotechnology startups are changing the paradigm on aging, disease, and human lifespan . Where science meets mission. Deep Expertise A decade of combined experience in longevity biotech investment and company creation. Network Unparalleled network of collabora … e of approaches and modalities. Simple and Accessible Healthspan Capital's rolling fund lets investors start investing in longevity in a way that's simple and flexible -- all through AngelList. Portfolio View all Founders Nathan Cheng General Partner Nathan Cheng is the Program Director of the On Deck Longevity Biotech and the Longevity Biotech Fellowship. He is also the founder of Longevity Marketcap, the most widely read newsletter on investing in longevity, Longe … in the biology of aging at the Gulbenkian Institute, awarded the Skaggs-Oxford fellowship at the Scripps Research Institute, and a SENS Foundation Scholar at the Buck Institute for Research on Aging. He was in the DPhil (PhD) program at Oxford as a Clarendon Scholar focusing on the biochemistry of aging, and completed a dual MSc in Life Science Business Management and Molecular Neuroscience from the University of Amsterdam as an Amsterdam Excellence Scholar. Michael Chinen G … s been recognized with several awards, including a Breakthroughs in Gerontology Award from the Glenn Foundation, an Alzheimer’s Association Young Investigator Award, an Ellison Medical Foundation New Scholar in Aging Award, an Undergraduate Research Mentor of the Year Award, and a Murdock Trust Award. In 2011, he was named the Vincent Cristofalo Rising Star in Aging Research by the American Federation for Aging Research and appointed as a Fellow of the Gerontological Society … t Apollo Health Ventures, the first and largest LongBio-focused venture capital fund and company builder in the world. He conducted his doctoral training at the Stem Cell Institute of Harvard University (focused on muscle stem cells) and the University of Copenhagen. He also holds an MSc and BSc in Molecular Biomedicine, a 6 year program at the U
Karl is always clear and straight forward and his website is a goldmine for anyone wanting to know more about longevity biotech (or aging therapeutics or any other definition you like). Curing aging… | Marco Dotto LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at a … rebuttals to longevity objections. I tried to make this the definitive work of scholarship in this area: 1. identifying 7 categories of counterarguments 2. collecting & categorizing 43 rebuttals to 11 objections 3. comprehensively reviewing prior rebuttal collections 4. I cite more sources & hard numbers for some important rebuttals where prior work often just made claims. Eg: quantitative comparison of population pressure from reduced aging deaths vs. from fertility … or care that connects the dots. Geronimus gave us the framework. Now we need to apply it—especially for conditions like G6PD deficiency, where those most at risk are often overlooked. The science is here. What’s missing is attention—and action. References in the comments. Scientific References 1. The original weathering hypothesis Geronimus AT. (1992). The weathering hypothesis and the health of African-American women and infants: evidence and speculations. Ethnicity & Di
Rejuvenation Startup Summit 2024 announces first set of speakers - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Rejuvenation Startup Summit 2024 announces first set of speakers November 8, 2023 | 5 min read Twitter LinkedIn Facebook Email Print Join the largest in-person gathering of CEOs from the worldwide Rejuvenation & Longevity biotech sector Join the largest in-person gathering of CEOs from the worldwide Rejuvenation &am … e Healthy Longevity Clinic and Managing Partner of LongevityTech.fund Brian Kennedy, Professor at the National University of Singapore Eric Verdin, CEO and president of the Buck Institute for Research on Aging Investors on stage: Jens Eckstein, Investment Partner at Hevolution Alex Colville, Co-Founder, General Partner at Age1 Jan Adams, Partner at Apollo Health Ventures Sergey Jakimov, Managing Partner at LongeVC Marc P. Bernegger, Founding Partner … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Longevity biotech matures with defined diseases and therapeutic programs | Marco Quarta posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or … rmacokinetics, and the translational and regulatory challenges shaping clinical application. 🔗 Find out more about the Special Issue using the link below: https://brnw.ch/21x3hDD 🕑 The deadline for manuscript submissions is 30 November 2026. 🎉 We warmly invite you to contribute as authors and reviewers! Please feel free to follow our LinkedIn account Bioengineering MDPI ! #MDPI #OpenAccess #Bioengineering #Nanoparticles #DrugDelivery #NanomedIcine #TargetedTherapy #Persona … port this post Longevity biotech NewLimit has closed a $435 million Series C to fund its first human clinical trial of a cell age reprogramming therapy. “We imagined it would take five years or more before our fundamental science was mature enough to start developing medicines,” Jacob Kimmel, CEO of NewLimit, wrote in a blog post. “The science moved faster than we anticipated. We began developing our first medicines ahead of schedule in 2025.” Read more on BioXconomy ! https:
J.P. Morgan Healthcare conference is more exciting than ever and, as expected, there’s a lot of interest for longevity biotech companies like Rubedo Life Sciences If you want to invest in clinical… | Marco Dotto LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any
Longevity Biotech PreJPM Event by The Longevity Investor Network · Luma Discover Events Sign In Hosted By Javier Contact the Host Report Event Featured in JPM Healthcare Week Longevity Biotech PreJPM Event by The Longevity Investor Network Hosted by Javier Shack15 San Francisco, United States Registration Past Event Please click on the button below to join the waitlist. You will be notified if additional spots become available. Join Waitlist You will be asked to verify token ownership with your wallet . About Event The event is full!! We will admit additional people from the waitlist if new … adraScope Ventures, will share real-life stories about how the companies in the fund’s portfolio are solving biological aging. quadraScope invests in early-stage healthcare companies that enable disease treatment and prevention through biological age reversal. 📝 DETAILS: • Why join? This event offers a unique opportunity to dive into new topics, connect with like-minded individuals, and open doors to exciting possibilities—even the chance to build and/or invest in y … etancourt - Presenting real-life stories about how companies in the Quadrascope fund portfolio are solving biological aging and what is the future of longevity VentureCapital. • 5:50PM-6:20PM: Networking 🤝 INVESTOR ATTENDEES: Investors From: Longevity Investor Network, Longevity Vision Fund, BoxOne Ventures, SOS Ventures, Maximon, Juvenescence, 5AM Ventures, CambrianBio, AltosLabs, Canaan Partners, LongeVC, Methuselah Foundation, CurieBio, Centenarian Fund, Formic Ve
Newsroom - Longevity Biotech Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM 2026 Newsroom Longevity Biotech attends the JP Morgan Healthcare Conference 2026 January 12-16, 2026 — San Francisco, CA 2025 Newsroom Longevity Biotech Australia initiates Phase 1b Multiple Ascending Dose (MAD) Clinical Tria … heimer’s Disease Summit July 15, 2020 – Virtual Event Longevity Biotech awarded grant by Department of Defense for ALS April 1, 2020 – Philadelphia, PA Longevity Biotech will be attending the JP Morgan Healthcare conference January 12 – 16, 2020 – San Francisco Privacy Policy | Cookies Policy | Terms & Conditions linkedin © 2026 Longevity Biotech. All Rights Reserved Close Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Ca
Longevity Biotech will be attending the JP Morgan Healthcare conference - Longevity Biotech Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM Newsroom Longevity Biotech will be attending the JP Morgan Healthcare conference By kapp No Comments January 6 – 10, 2019 – San Francisco Longevity Biotech will b
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Alice Gilman - BIO International Convention 2026 Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! June 7-10 | Philadelphia Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs International Visitors Why Attend Visa Invitation Letter Request Tips for International Visitors Share On Social Media For Press Media Resource Center Media Registration Engaging with the Media Request Media List Press Releases Stay in Touch Contact Us Join our mailing li … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung … AI in aging research. Alice is a Fellow and Counselor at the Longevity Biotech Fellowship and an Advisor to The Residency, an incubator backed by Sam Altman supporting emerging biotech founders. She has spoken at leading industry events including BioFuture, LSX World Congress, and Vision Weekend Puerto Rico 2025, sharing insights on the future of longevity and regenerative biotech. Previously, Alice contributed to operations at Symbiont Labs, a deep-tech venture focused on h
Longevity Conferences & Events | Join Longevity Join Longevity Home Explore Resources About Partnership Partnership Longevity Conferences & Events Discover the best conferences and events in the longevity field. Connect with researchers, entrepreneurs, and advocates working to extend healthy human lifespan. Filter Conferences Conference Type Research Industry Community Investment Mixed Focus Area Scientific Business & Investment Community & Advocacy Clinical & Medical Technology & Innovation Showing 10 of 10 conferences Longevity Investors Conference Upcoming Investment … 0 CHF Target Audience: Institutional Investors Private Investors Family Offices Fund Managers + 1 more Key Topics: Investment Opportunities Longevity Trends Rejuvenation Technologies + 2 more Notable Features: • Exclusive Setting • 20% Acceptance Rate • Networking App Visit Website TransVision Madrid: International Longevity Summit Upcoming Community Community & Advocacy El Ilustre Colegio de Medicos, Madrid, Spain • Oct 1, 2025 - Oct 2, 2025 Organized by: TransVision Mad … rmat • Clinical Focus • Practitioner Networking Visit Website Longevity Biotech Fellowship Upcoming Community Business & Investment Valencia, Spain • Sep 22, 2025 - Sep 29, 2025 Organized by: Longevity Biotech Fellowship An elite community gathering for builders and investors in longevity biotech. Highly selective program focused on high-impact ventures and fostering collaboration in the longevity ecosystem. Target Audience: Entrepreneurs Investors Biotech Builders Indust … repreneurship + 2 more Notable Features: • Elite Community • Highly Selective • Fellowship Program Visit Website SEMAL Upcoming Research Clinical & Medical Madrid, Spain • Oct 3, 2025 - Oct 4, 2025 Organized by: SEMAL Spanish conference focused on longevity medicine and anti-aging research, bringing together medical professionals and researchers in the Spanish-speaking longevity community. Target Audience: Medical Professionals Researchers Healthcare Practitioners Student … ity Community Get Involved in Longevity Join Longevity Helping people navigate, apply, and support longevity Home The Longevity Map Get Involved Apply Longevity Longevity Explorer Longevity Lifestyle FAQ Newsletter Signup News & Opportunities Longevity Explorer Join Our Projects About Contact © 2025 Join Longevity. All rights reserved.
Investor perspective... - Longevity Investors Conference Facebook Log In Longevity Investors Conference's Post Longevity Investors Conference July 24, 2025 · Shared with Public Investor perspective meets founder vision. How do you navigate the risks to unlock the immense rewards of longevity biotech? We're bringing both sides of the table together for a can't-miss panel at the Longevity Investors Conference - Navigating Biotech Investments: Risks and Rewards. Get practical guidance on de-risking your portfolio from three industry powerhouses: David Gobel, CEO at Methuselah Found
Longevity Biotechnology Association’s (LBA) Investors Conference - Eos SENOLYTIX Skip to main content Hit enter to search or ESC to close Close Search search Menu About Us MitoXcel™ Technology Pipeline Sarcopenia/Sarcopenic Obesity Aging Research Hub Investors Contact Us search Longevity Biotechnology Association’s (LBA) Investors Conference October 23rd, 2025, NYC Kevin Slawin, M.D., Founder and CEO Eos SENOLYTIX An exclusive, invitation-only gathering taking place on Thursday October 23, 2025 in New York City. The event will convene a select group of investors, early-stage longevity biotech
How Asia is Pioneering Longevity Biotech HOME Pharma Generics Drug Discovery CMC & Manufacturing Clinical Trials New Drug Applications BioTech Biologics Stem Cells Vaccines Therapeutics MedTech Medical Devices Medical Diagnostic BioServices Contract Research Clinical Research Contract Manufacturing Pre Clinical Development Clinical Trial Phase Healthcare Digital Health COVID19 Artificial Intelligence Healthcare Logistics & Clinical Supply Chain Bio LAB Lab Products Lab Safety Lab Management Lab Design HER Health Cell & Gene Specials Bio interaction Premium Article Biopreneurs Indus … rdquo; said Boyang Wang, Founder, Immortal Dragons , a purpose-driven longevity fund that wants to make death optional. Launched in August 2025, Singapore-based Immortal Dragons began operations with $40 million under management, mostly contributed by Wang himself, and is focusing on early-stage companies developing treatments to extend life. In April 2025, another dedicated fund, Seveno Capital, officially launched with a $70 million commitment from its founder, entrep … ;Asian government funding faces bureaucratic challenges and political risks, as fund performance is closely linked to officials' political careers. Poor outcomes are poorly tolerated and may result in political repercussions. However, a significant wave of serial entrepreneurs—particularly former tech founders in their 40s seeking healthier, longer lifespans—represents a crucial alternative. These private investments operate independently of government funding but … accept the terms & condition & Privacy policy Sign Up Forgot Password Email id Submit Close × Subscribe To Our Newsletter Email ID I accept the terms & condition & Privacy policy SUBSCRIBE! Close Guía completa para jugadores que buscan una plataforma moderna, segura y entretenida En un mercado digital cada vez más competitivo, los usuarios buscan experiencias que combinen simplicidad, variedad y transparencia. Al explorar opciones de entretenimiento en línea, resulta e … d-time tournaments, confirm that the rules detail how points are earned and how prize pools are distributed. To help you scan core offerings at a glance, review the table below. It summarizes categories that typically influence long-term satisfaction, including user experience, bonus structure, and support availability across devices. Category Wh
Neurodegenerative Diseases Research | Longevity Biotech Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM PRECISION APPROACH TO ADDRESS NEURODEGENERATIVE DISEASES Learn More Parkinson's Disease Clinical Trial Learn More Pipeline Learn More Precision Neuroscience Learn More Hybridtide™ Platform Le
Tally Health Acquired by Infinite Epigenetics | Tally Health posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Linke
Neurodegenerative Diseases Research | Longevity Biotech Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM PRECISION APPROACH TO ADDRESS NEURODEGENERATIVE DISEASES Learn More Parkinson's Disease Clinical Trial Learn More Pipeline Learn More Precision Neuroscience Learn More Hybridtide™ Platform Le
Rejuveron lands $75m to advance healthy aging portfolio; expands focus in Middle East Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search DiamiR, … ience , a brain synapse regeneration company. This company was founded by Nobel Prize winner Dr Thomas Sudhof, who also serves as a Venture Partner at Catalio. This investment aligns with Rejuveron’s long-term vision to back pioneers in the field of aging and assist them in translating scientific discoveries into transformative medicines. Apeiron boss Christian Angermayer is co-founder of Rejuveron. “Our mission is to develop therapies to tackle diseases of aging to pro … n ageing. This is why I am especially excited to team up with Catalio and Nobel Prize winner, Dr Thomas Sudhof.” Targeting hallmarks of aging Founded in 2019 by Angermayer and entrepreneurial scientist Matthias Steger, Rejuveron’s approach encompasses programs specifically focused on preventing, repairing, or reversing the hallmarks of aging, spanning early-stage drug discovery to clinical development. The company’s current portfolio includes a revolutionary small molec … ghlights new GLP-1 care model GARM Clinic debuts world’s first Klotho longevity residency You might also like Scribe lands $25m to advance heart disease gene therapies ŌURA-LillyDirect collab highlights new GLP-1 care model GARM Clinic debuts world’s first Klotho longevity residency Peers Capital bets on prevention before the pivot NorthStrive eyes emerging GLP-1 opportunity: muscle preservation Danny Sullivan Danny has worked in technology communications for more than 20 yea
- LONGEVITY GLOBAL Skip to content LONGEVITY GLOBAL SF | NYC | UAE | BOS | SD | ATX | CO | HYD | CHI | LON | PHX | LA | DEU Menu + × expanded collapsed Events Calendar of longevity events Brain Optimization Summit 2026 Longevity Global Summit 2026 AI x Longevity Summit (NYC) Aging Code Summit 2026 Longevity Innovation Forum (SD) Event Photos Community Become a member Community Chapters Longevity CO Longevity SF Longevity SD Longevity NYC Longevity BOS Longevity Global ATX Longevity CHI Longevity MEL Longevity DEU Longevity LON Resources About Substack YouTube Discount Marketplace Jobs Bo … or government representative. Interested in showcasing your products/services? Apply to Sponsor OUR SPEAKERS See below for our confirmed speakers for 2025. Eric Verdin, MD President & Professor Buck Institute Martin Kawalski, MD, PhD Sleep Researcher Stanford Josh Helman, MD CMO & Physician Alzheimer’s Treatment Centers of America Janine Senstack, PhD CSO and Co-founder Junevity Gil Blander, PhD Founder InsideTracker Kayla Barnes-Lentz Co-Founder of The Health … Founder InsideTracker Kayla Barnes-Lentz Co-Founder of The Health Optimization Fund, Founder of the Female Longevity Protocol David Barzilai, MD, PhD, MBA Founder & CEO Barzilai Longevity Joanna Bensz CEO & Founder Longevity Center Hazel Szeto, MD PhD CSO, Founder Social Profit Network, Stealth Biotherapeutics Robert Cargill, PhD Venture Partner Quadrascope Jana Buzkova, PhD COO & Co-founder NADMed Xiaoxi (Sofie) Wei, PhD Founder & CEO X-Therma Lisa Lambie, M … PhD Founder & CEO X-Therma Lisa Lambie, MBA Managing Partner Maroon Venture Fund Armand Cognetta, PhD CoFounder & CEO General Proximity Helen Blau, PhD Professor & Co-founder Stanford, Myoforte Eric Morgen, MD COO & Co-founder BioAge Labs Dylan Livingston Founder & CEO The Alliance for Longevity Initiatives Karl Pfleger, PhD Investor, Founder & Head Agingbiotech.info Louise Hecker, PhD Assoc. Professor, Founder& CSO Baylor, Fibronox Salah Mahmoudi, … 6 Summit and a feature article in the Longevity Global Substack and Newsletter. Apply to pitch CONGRATS TO OUR 2024 PITCH COMPETITION WINNER! Michael Florea, PhD Co-founder and CEO Olden Labs CONGRATS TO OUR 2023 PITCH COMPETITION WINNER! Robert Lustig, MD MSL Co-founder and CMO Biolumen WATCH PRESENTATIONS Interested in the latest in cutting edg
Neurodegenerative Diseases Research | Longevity Biotech Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM PRECISION APPROACH TO ADDRESS NEURODEGENERATIVE DISEASES Learn More Parkinson's Disease Clinical Trial Learn More Pipeline Learn More Precision Neuroscience Learn More Hybridtide™ Platform Le
LONGEVITY BIOTECH, INC. Top 13F Holdings We give you the access and tools to invest like a Wall Street money manager – at a Main Street price. 0 Key Features Backtester Combined Holdings Excel Add-in 13F Fund Performance Evaluator Developer API 13F Stock Screener 13F Heat Map About Us Getting Started How WhaleWisdom Can Help FAQ About WhaleWisdom Contact Us Premium Subscriptions News and Articles TOU Disclaimer Privacy Policy Trademarks LIMIT THE USE OF MY SENSITIVE PERSONAL INFORMATION All text and design is copyright © 2026 WhaleWisdom.com. All rights reserved.
Entrepreneurship, Longevity, and Biotech Conference 2023: Paving the Way for Age-Defying Solutions | FAU Business FLORIDA ATLANTIC UNIVERSITY ® COLLEGE OF BUSINESS QUICK LINKS Alumni Business Communications Economics Executive Education Faculty in the Media Faculty Research Finance Giving Health Administration Hospitality & Tourism Management Information Technology & Operations Management Management Programs Marketing Masters & Ph.D. School of Accounting open menu close menu College of Business Home Page College of Business Newsroom Business Features Search SEARCH QUI … ments Faculty/Staff Research Archives 2026 E-NEWS SIGN-UP sign up Apply Now ---> Privacy Policy REGULATIONS & POLICIES CONSUMER INFORMATION Employment Opportunities Get Help Accessibility Contact us Florida Atlantic University 777 Glades Road Boca Raton, FL 33431 Campuses: Boca Raton Dania Beach Davie Fort Lauderdale Harbor Branch Jupiter FAU Business facebook instagram linkedin twitter youtube FAU Executive Education facebook instagram linkedi
Neurodegenerative Diseases Research | Longevity Biotech Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM PRECISION APPROACH TO ADDRESS NEURODEGENERATIVE DISEASES Learn More Parkinson's Disease Clinical Trial Learn More Pipeline Learn More Precision Neuroscience Learn More Hybridtide™ Platform Le
Biotech Inscript News Press Releases About Publications Sign in Subscribe Pharmaceuticals Medical Tech Bioinformatics Agriculture & Environmental Industrial Biotech Regenerative Medicine Synthetic Biology Genomics Genetic Engineering & Gene Editing Axolotl Biologix and Carmell Therapeutics Merge to Pioneer Regenerative Medicine Advancements Muhammad Sep 13, 2023 2 min Flagstaff's Axolotl Biologix merges with Carmell Therapeutics, a major move in regenerative medicine. $65 million initial value with potential for $75 million more in milestone payments. Pioneering innovations expect
Neurodegenerative Diseases Research | Longevity Biotech Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM PRECISION APPROACH TO ADDRESS NEURODEGENERATIVE DISEASES Learn More Parkinson's Disease Clinical Trial Learn More Pipeline Learn More Precision Neuroscience Learn More Hybridtide™ Platform Le
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Neurodegenerative Diseases Research | Longevity Biotech Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM PRECISION APPROACH TO ADDRESS NEURODEGENERATIVE DISEASES Learn More Parkinson's Disease Clinical Trial Learn More Pipeline Learn More Precision Neuroscience Learn More Hybridtide™ Platform Le
Neurodegenerative Disease | Longevity Biotech | Approach Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM Menu Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications Immune Rebalancing Longevity Biotech’s therapeutic pipeline is currently focused on changing the treatment paradigm
%PDF-1.3 %��������� 3 0 obj > stream x�]�$�q��OQÞ��YuW�.ze�ܥD�4{m��P0�� K��G�{�Kd&���Q=C�FLo]Y@�P.�/�\���d� ~**�3�O?�TU֭=��1uэS9��?��/�UYUSS���hF{~L��0�b0��������������b��cq���?]���#���8���c��W|���qC�==���ك��'���?}�/�� ?���5���7z����[ ]+�5~��'�}�X�[�������a���\ƐGK]W}Y� ����e�>���7 آ�5u���Л�j� ��5e���\�m w? o�X�!�Mt ���S�C�б�:ASl銦�r� ��� /hC|�o���.�%������t��0ԑ$LC]v]��� ��q�Xh�;k�t�1�Ŀʇ�8ֺj������� Hb h�������M�$?�a�+ �O���A !� ����q0� :ˎ1�BKH����TT�P C�g6?f�˱����3pH���.�C�ɉ?�-��N� k8G��q, s���N���/?�����~���˿��thJ n�}� C�N_�h�w���
Daewoong Pharmaceutical Acquires Turn Bio's ERA Platform · Discoperi M&A Intelligence Home / Deals / Daewoong Pharmaceutical / Turn Biotechnologies Verified Healthcare Asset Acquisition 26 May 2026 Daewoong Pharmaceutical acquires the assets of Turn Biotechnologies Daewoong Pharmaceutical → Turn Biotechnologies · Healthcare · Asset Acquisition Close date 26 May 2026 Announced 26 May 2026 Deal value Undisclosed Quality score 72% Acquirer HQ 🇰🇷 Target HQ 🇺🇸 AI-generated analysis Daewoong Pharmaceutical’s acquisition of Turn Biotechnologies’ ERA platform represents a strategic move to … ate plausibility 1.00 Value plausibility 0.60 Entity quality 1.00 See an error? Submit a correction → · All corrections reviewed within 24 hours. Key facts Sector Healthcare Deal type Asset Acquisition Value Undisclosed Close date 26 May 2026 Announced 26 May 2026 Quality score 72% Acquirer HQ 🇰🇷 Target HQ 🇺🇸 ☆ Save deal Export this deal ↓ Export JSON ↓ Export CSV Related deals
Neurodegenerative Diseases Research | Longevity Biotech Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM PRECISION APPROACH TO ADDRESS NEURODEGENERATIVE DISEASES Learn More Parkinson's Disease Clinical Trial Learn More Pipeline Learn More Precision Neuroscience Learn More Hybridtide™ Platform Le
Merger and Acquisition (M&A) Deals in Pharmaceuticals, Biotechnology and Diagnostics 2021-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Confer … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … Forecasts, Till 2035 - Distribution by Source of Cell Line / Expression System, Application of Cell Line, Company Size, and Key Geographical Regions  Report 455 Pages December 2025 Global From €4310 EUR $4,799 USD £3,723 GBP Cell Therapy Media Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Product, Type of Cell Therapy, Scale of Operation, Type of End User and Key Geographical Regions  Report 250 Pages December 2025 Global Fr … echnology and Diagnostics 2021-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-pattern="^[^<>{}]*$" data-val-required="First Name field is required!" id="ProductEnquiry_FirstName" maxlength="50" name="ProductEnqu
Biopharmaceutical Company | Longevity Biotech | About Us Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM Menu About Us Leadership Team Board Of Directors Scientific Advisors Careers Careers Longevity Biotech is an Equal Opportunity Employer. Please check back as we routinely update this page. Longevit … not work with recruiters – principals only. Cell Biology Technician INFO APPLY Privacy Policy | Cookies Policy | Terms & Conditions linkedin © 2026 Longevity Biotech. All Rights Reserved Close Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM CONTACT link
Biopharmaceutical Company | Longevity Biotech | About Us Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM Menu About Us Leadership Team Board Of Directors Scientific Advisors Careers Careers Longevity Biotech is an Equal Opportunity Employer. Please check back as we routinely update this page. Longevit … not work with recruiters – principals only. Cell Biology Technician INFO APPLY Privacy Policy | Cookies Policy | Terms & Conditions linkedin © 2026 Longevity Biotech. All Rights Reserved Close Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM CONTACT link
Longevity Biotech Drug Market Research Report 2034 Report Store Aerospace & Defense Automotive & Logistics Banking, Financial Services & Insurance Construction & Manufacturing Consumer Goods Energy & Power Food & Beverage Healthcare ICT, Semiconductor & Electronics Materials & Chemicals Trending --> Press-Release Blog --> About Us Our Team FAQs Contact Us Search Search reports. Longevity Biotech Drug Market Research Report 2034 Get free sample report Request for Customiztion Buy Now Home Healthcare Diagnostics & Biotech Longevity Biotech Drug Market Research Report 2034 Longevity Biotech Drug … TOR Inhibitors, Telomere Restoration Therapies, Mitochondrial Rejuvenation), by Application (Age-Related Disease Prevention, Muscle & Metabolic Decline, Cognitive Decline & Neurodegeneration, Cardiovascular Aging, Immune System Restoration), by End User (Biopharmaceutical Companies, Academic Research Centers, Longevity & Anti-Aging Clinics, Government Health Agencies) Author : Raksha Sharma Fact-checked by : V. Chandola Editor : Shruti Bhat Last Updated: June 11, 2026 Upcomin … s Market Outlook Regional Outlook Growth Drivers By Type What Are Senolytics By Application Fastest Growing Application By End User End User Growth Segment Comparison Opportunities & Threats Competitor Outlook Market Concentration Report Scope Segments Frequently Asked Questions Table Of Content Methodology Related Reports Customize This Report Ask for Research To Be Focused On Specific Regions or Segments Receive Data As Per Your Format and Definition Companies Profiled base … traordinary surge of venture capital, strategic corporate, and sovereign wealth fund investment, creating a deep and expanding pool of capital to fund drug development from discovery through clinical trials. Notable funding milestones include Altos Labs raising $3 billion at inception, representing one of the largest Series A rounds in biotech history. BioAge Labs, Retro Biosciences, and others have each raised hundreds of millions of dollars in recent funding cycles. Beyond … hrough the 2026-2034 forecast period. Longevity Biotech Drug Market Analysis by Application By application, the longevity biotech drug market is segmented into Age-Related Disease Prevention, Muscle and Metabolic Decline, Cognitive Decline and Neurodegeneration, Cardiovascular Aging, and Immune System Restoration. Age-Related Disease Prevention w
Neurodegenerative Diseases Research | Longevity Biotech Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM PRECISION APPROACH TO ADDRESS NEURODEGENERATIVE DISEASES Learn More Parkinson's Disease Clinical Trial Learn More Pipeline Learn More Precision Neuroscience Learn More Hybridtide™ Platform Le
Longevity Biotech Careers, Perks + Culture | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Companies Longevity Biotech Teams Longevity Biotech Save Saved Philadelphia 4 Total Employees Year Founded: 2010 View Website Overview Jobs Offices Is This Your Company? Claim Profile Biotech Pharmaceutical Longevity Biotech develops a new class of therapeutics via artificial protein technology that focuses on pharmaceutical preparation. Longevity Biotech Offices OnSite Workspace Employees work from physical offices. Typic
Hexembio Featured in Forbes on Longevity Biotech | Public Ventures posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to … 𝗿𝘀 𝗛𝘂𝗺𝗮𝗻 𝗛𝗲𝗮𝗹𝘁𝗵 𝗘𝗜𝗦 𝗚𝗿𝗼𝘄𝘁𝗵 𝗙𝘂𝗻𝗱. This is an evergreen fund that aims to provide access to a curated portfolio of growth-stage UK biotech and human health companies working across oncology, neuroscience, advanced therapeutics, AI-enabled drug discovery and biotech enablers. Built from the wider o2h ecosystem: • 40+ biotech companies supported • £300m+ follow-on capital attracted • 7 companies progressed to clinical stage 👉 If you would like to learn … progressed to clinical stage 👉 If you would like to learn more or discuss the Fund further, please reach out to us at [email protected] . 👇To learn more about the Fund and the wider o2h Ventures ecosystem, access the brochure via link in the comment below. #o2hVentures #EIS #UKBiotech #SEIS #Biotech 13 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Chris White 1mo Report this post o2h Ventures have launched our latest EIS Growth Fund. … ls (including warnings about this being a high-risk investment) are below. This fund is investing in our existing later stage biotech portfolio, so will be going into companies we have been very close to for many years and know well. There will be a good mix of therapeutics and biotech services businesses (ie revenue-generating). o2h's investors are typically people who are either passionate about biotech/life sciences, or generalist investors looking for some proper diversif … 𝗿𝘀 𝗛𝘂𝗺𝗮𝗻 𝗛𝗲𝗮𝗹𝘁𝗵 𝗘𝗜𝗦 𝗚𝗿𝗼𝘄𝘁𝗵 𝗙𝘂𝗻𝗱. This is an evergreen fund that aims to provide access to a curated portfolio of growth-stage UK biotech and human health companies working across oncology, neuroscience, advanced therapeutics, AI-enabled drug discovery and biotech enablers. Built from the wider o2h ecosystem: • 40+ biotec
Neurodegenerative Diseases Research | Longevity Biotech Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM PRECISION APPROACH TO ADDRESS NEURODEGENERATIVE DISEASES Learn More Parkinson's Disease Clinical Trial Learn More Pipeline Learn More Precision Neuroscience Learn More Hybridtide™ Platform Le
Longevity List - Find jobs, companies, and investors in the longevity industry Sign in or Register Add a listing View all results No results Jobs Database More arrow_drop_down Clinical Trials Newsletter Coworking Events Blog Supporters About Add a listing We Fight Aging. Find jobs, companies, and investors in the longevity industry. See longevity database {{ listingType.name }} prev next {{label}} my_location my_location {{label}} {{label}} search Search {{label}} {{label}} my_location my_location {{label}} search Search {{label}} {{label}} my_location my_location {{label}} search Search Popul … e your career in aging with networking + mentorship. Join the Longevity Biotech Fellowship. Apply now Longevity Startups Database Discover companies, investors, clinical trials, and more. See longevity database Latest Jobs Research Engineer - Turing & Ada Relation Therapeutics Full time London, Greater London About Relation Relation is an end-to-end biotechnology company developing transformational medicines, with technology at our core. Our... January 26, 2025 Computer Scien … ience and deep technology to create the unimaginable. Healthspan Capital a seed fund supporting longevity and geroscience companies developing therapies that extend healthy lifespan. Seed +2 Next Play Ventures Coaching and investing in entrepreneurial leaders building world-class, purpose-driven orgs (emphasis in longevity) Series A +1 Cambrian Biopharma Developing new therapies to extend healthy lifespan. Parent company Seed +1 R42 Ronjon Nag's Longevity and AI Fund See … chnologies raises $5M seed round Michael Greve announces 300M EUR commitment to fund longevity biotech companies How to get a job at a longevity startup Connect and build longevity startups Join the Longevity Biotech Fellowship. I believe that aging is a disease. I believe it is treatable. I believe we can treat it within our lifetimes. And in doing so, I believe, everything we know about human health will be fundamentally changed. — David A. Sinclair , Lifespan:
L Cell joins Revive ME as a startup exhibitor, showcasing their science-backed longevity supplements. | Revive ME posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By cli
Biopharmaceutical Company | Longevity Biotech | About Us Skip to main content linkedin CONTACT Hit enter to search or ESC to close Close Search Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM Menu About Us Leadership Team Board Of Directors Scientific Advisors Careers Careers Longevity Biotech is an Equal Opportunity Employer. Please check back as we routinely update this page. Longevit … not work with recruiters – principals only. Cell Biology Technician INFO APPLY Privacy Policy | Cookies Policy | Terms & Conditions linkedin © 2026 Longevity Biotech. All Rights Reserved Close Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM CONTACT link
%PDF-1.4 %���� 1 0 obj > endobj 6 0 obj > endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj > endobj 5 0 obj > endobj 7 0 obj > endobj 8 0 obj > endobj 9 0 obj > endobj 10 0 obj > endobj 11 0 obj > endobj 12 0 obj > endobj 13 0 obj > endobj 14 0 obj > endobj 15 0 obj > endobj 16 0 obj > endobj 17 0 obj > endobj 18 0 obj > endobj 19 0 obj > endobj 20 0 obj > endobj 21 0 obj > endobj 22 0 obj > endobj 23 0 obj > endobj 24 0 obj > endobj 25 0 obj > endobj 26 0 obj > endobj 27 0 obj > endobj 28 0 obj > /Font 1837 0 R >> endobj 29 0 obj > endobj 30 0 obj > stream x��VMk 9����y�rU�$U�1df�����2�ܽ��0� … ����c��[ˏݱ�[ ������ ����������Ͽ�wċ�y ]j��#g~�_3q����>��SvWr���o���s�}��:rFP\]�{3���F�̓�s�\T&�Z� � �.�?��3��� I��=��'kHY�:|�ϠW�*�QF�� �!�����P��-�W zJ9�Tq��(��ص���s����/� �yv����.B&x�9�c�#F��oE�ONj5^�1����K�5��4�� �3�F0��U fɺ���� �*�+�7P����H���M=˼���o]����LͽK���x�� �g���d ��oq> �.|��(# y�SL�k�h�|,�5���!��7U]2iL�~��?x�\S3wf����Zv���� _�k4# 0fc:�b�sܯB9�s�Bc H|a�.�/]K]WF�i�H�KT��]����pF"%���#�\���%=:���m���S k�"����X4ie�x��}KeC+�
Day two of Longevity Fest is about to kick off! It’s exciting to be here, and the @redefiningmedicine team has done a fantastic job of putting this program together. @draustinperlmutter is about to give a keynote talk and I’m headed that way. Just a reminder: @bigboldhealth is in the exhibit hall at Booth 6098 and we hope you’ll stop by. | Jeffrey Bland, PhD
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Boston Hosts the Global Longevity Biotech Summit - FIFTIERS Now Reading Boston Hosts the Global Longevity Biotech Summit 0 Comments 4º CONGRESO FIFTIERS FIFTIERS ACADEMY TEST EDAD MENTAL NEWS Who We Are Contact Advertise on FIFTIERS ACADEMY FiftyShop AGE FRIENDLY Country Partner 4th Congress EVENTS Boston Hosts the Global Longevity Biotech Summit by FIFTIERS FIFTIERS FIFTIERS | Life Begins at 50. La vida comienza a… Read Next FIFTIERS MAGAZINE goes global with a bilingual edition and a Christmas Special starring Jennifer Aniston This week, the U.S. city becom
Longevity Leadership Conference · Luma Discover Events Sign In Featured in Los Angeles Presented by Healthspan Collective Follow The Healthspan Collective is an evidence-based, multi-expert ecosystem dedicated to helping people extend their healthy years through trusted knowledge, community, and experiential learning. Hosted By Healthspan Productions Adam Torres Chirag Sagar PITCHFEST 2026 | Startup World Cup by Syndicate AI Steven A Harms Contact the Host Report Event AI Wellness Featured in Los Angeles Longevity Leadership Conference Healthspan Collective Register to See Address Los Angeles,
A4LI Longevity Investors Summit - Alliance for Longevity Initiatives Skip to content Dr. Mehmet Oz’s Opening Remarks at A4LI’s 2025 Congressional Briefing Join A4LI Become a Member Become a Sponsor Get Involved Our Advocacy Publications Longevity Science Caucus Podcasts H-SPAN Podcast Scientific Spotlights About Events A4LI H-SPAN Summit D.C. Past Events A4LI Longevity Investors Summit A4LI 2025 D.C. Summit Recap DC Fly-In 2024 Geroscience Education Reception LogIn Join A4LI Become a Member Become a Sponsor Get Involved Our Advocacy Publications Longevity Science Caucus Podcasts H-SPAN Podcast … health initiatives impacting more than 4 million patients. She completed an NIH fellowship in Insulin Resistance/Metabolic Syndrome at Stanford, later served as an Assistant Professor there, and continues to advise healthtech startups. Chris Bradley, PhD CEO Matter Bio Bio Christopher “Chris” Bradley is the CEO and Co-Founder of Matter Bio, a biotechnology company focused on preserving genomic integrity and extending human healthspan. He is a serial entrepreneur with a backgr … eneurs through organizations like Global Biotech Revolution, TKS, and the Thiel Fellowship, advancing innovation in biotechnology and longevity. 11:50 AM Watch now! Investor Panel Funding the future of healthy aging. Carla Pareja Paris Associate, Zuber Lawler LLP MODERATOR Bio Carla Pareja Paris focuses on advising corporate clients in various stages of their life cycle, ranging from startups to well established multinational clients conducting domestic and cross-border activ … operations by US companies abroad. Lisa Lambie Managing Partner Maroon Venture Fund I LP Bio Lisa Lambie is the Managing Partner for Maroon Venture Fund I LP ~ a U.S. focused venture capital fund investing anchor capital (Seed to Series A+) to advance Healthy Aging, Healthspan & Longevity by closing material innovation and funding gaps in proactive/personalized, Preventative Healthcare & Precision Medicine for the early detection, diagnosis and reduction in chronic P … opulation Health conditions; and mitigation of direct Climate Impact on Health. Fund is anchored by its General Partners and consortium of investor-operators. Team (collectively) has a strong track record specifically in the Fund investment thesis sectors and investment stage of $960mm AUM delivering 5x+ MOIC to limited partners and 36 realized v
Scientific Program - Sciinov Conference Overview About Scientific Committee Become a Speaker Sponsor/Exhibit Organizer Info Speakers Speakers 5th edition 2027 Speakers 4th Edition 2026 Speakers 3rd Edition 2025 Speakers 2nd Edition 2024 Speakers 2023 Program Scientific Sessions Scientific Program Brochure Download Partners Information Important Dates Venue Guidelines Publication Pricing / Registration Quick Downloads News Reports Past Events Submit Abstract Help & Support Registration Overview About Scientific Committee Become a Speaker Sponsor/Exhibit Organizer Info Speakers Speakers 5th … nes Publication Pricing / Registration Quick Downloads News Reports Past Events Submit Abstract Help & Support Registration Scientific Program Engaging Presentations, Connect with Leading Experts from Around the Globe, and Network in a Collaborative Environment Beyond the Sessions HOME Scientific Program SCHEDULE OF EVENT List of Events Planned in This Conference DOWNLOAD SCHEDULE Day 1 Day 2 Day 3 07:30 AM - 09:00 AM 1 The Science Of Human Longevity Registration, Network … Awards Categories: Lifetime Achievement in Longevity Science Global Innovation Award Rising Startup of the Year Excellence in Preventive Healthcare Women Leaders in Longevity AI Innovation Award Special Features: Celebrity keynote guest Investor-hosted networking Media and press coverage 08:00 AM - 09:00 AM 1 Global Implementation & Future Of Healthspan Wellness Morning Experience Options: Longevity fitness session Mindfulness & stress reduction workshop Biohacking d
Longevity Biotech - 8th Treg-Directed Therapies Summit 2026 Skip to content This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 summit. March 24-26, 2026 | Boston, MA About About Event Blogs Events in the Series Hanson Wade Products What’s On? 2026 Full Event Guide 2026 Speakers Why Partner Why Partner 2026 Partners 2026 Media Partners Take Part Register Interest Contact Us Event Guide Register About About Event Blogs Events in the Series Hanson Wade Products What’s On? 2026 Full Event Guide 2026 Speakers Why Partner Why Partner 2026 Pa
Pre-clinical Development of LBT-3627, a Potential Neuroprotective and Anti-inflammatory Therapy for Parkinson's Disease | Parkinson's Disease JavaScript is currently disabled. Please enable JavaScript for an optimal experience. Skip to main content Animations Search Email Sign Up Log In Donate Now Home Page Are you looking for: ${result.term} Donate Now Menu Close Clear My Profile My Parkinson’s Library Log In Main navigation Why We Exist Why We Exist Our Mission Our Promise Our Impact Our Agenda Michael's Story Current Partnerships Parkinson's Research The State of the Field Our Res … on's Library Educational Guides For Researchers For Researchers Funding What We Fund Funding Opportunities Funded Studies Open Science & Research Integrity Resources Research Tools Data Resources Biospecimens Patient Engagement Research News Podcasts MJFF Scientific Publications Collaboration Collaborative Research Opportunities Industry Partners Working with Us Key Initiatives and Findings PPMI Clinical Study ASAP Initiative GP2 Take Action Take Action Donate Donate Now Ways … nical evaluation. Next Steps for Development: Should the first two aims of this proposal be successful, the next step would involve completion of a full Investigational New Drug set of studies and filing of the results with the FDA prior to Phase I clinical evaluation. Longevity Biotech has obtained quotes and secured agreements with leading Contract Research Organizations who are ready to initiate these studies. Researchers Howard E. Gendelman, MD Omaha, NE United States Vie
Longevity Events, Conferences & Summits 2026 Skip to main content Events Reports Pricing Blog FAQ Contact Find the right longevity events Search hundreds of conferences, summits, and gatherings worldwide — updated every week. Longevity events in 2026 span 400+ conferences, summits, and scientific meetings across 40+ countries, covering regenerative medicine, stem cell research, biohacking, and anti-ageing science. Q1 2026 Report is live Search Use natural language to find events by date, location, region, or topic List View Calendar View Showing 1 – 5 of 138 events International Conference
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
- LONGEVITY GLOBAL Skip to content LONGEVITY GLOBAL SF | NYC | UAE | BOS | SD | ATX | CO | HYD | CHI | LON | PHX | LA | DEU Menu + × expanded collapsed Events Calendar of longevity events Brain Optimization Summit 2026 Longevity Global Summit 2026 AI x Longevity Summit (NYC) Aging Code Summit 2026 Longevity Innovation Forum (SD) Event Photos Community Become a member Community Chapters Longevity CO Longevity SF Longevity SD Longevity NYC Longevity BOS Longevity Global ATX Longevity CHI Longevity MEL Longevity DEU Longevity LON Resources About Substack YouTube Discount Marketplace Jobs Bo … or government representative. Interested in showcasing your products/services? Apply to Sponsor OUR SPEAKERS See below for our confirmed speakers for 2026. More updates are coming soon. Eric Verdin, MD President & Professor Buck Institute Janine Senstack, PhD CSO and Co-founder Junevity Krista Ramonas , MD Founder, CEO & Physician LabXMD Ronjon Nag, PhD President, Adj. Professor R42 Group, Stanford Matthew “Oki” O’Connor Co-CEO Cyclarity Therapeutic … 6 Summit and a feature article in the Longevity Global Substack and Newsletter. Apply to pitch CONGRATS TO OUR 2025 PITCH COMPETITION WINNER! David Scieszka, PhD Co-founder and CEO Vertical Longevity Therapeutics CONGRATS TO OUR 2024 PITCH COMPETITION WINNER! Michael Florea, PhD Co-founder and CEO Olden Labs CONGRATS TO OUR 2023 PITCH COMPETITION WINNER! Robert Lustig, MD MSL Co-founder and CMO Biolumen WATCH PRESENTATIONS Interested in the latest in cutting edge longevity sc … ube Channel . PRESENT A POSTER Abstract submissions are due by December 1, 2026 Submit Abstract SPONSORS MEDIA SPONSORS ← Back You are Subscribed! Thanks for signing up for Longevity Global Newsletter. Email Subscribe to our Newsletter Submitting form Δ X LinkedIn YouTube Donate Become a member [email protected] Privacy Policy LONGEVITY GLOBAL , Newsletter Subscribe to the Longevity Global Newsletter Sign up for our email newsletter for longevity events and news. Ema